Phase 1 Trial of the TQB2928 Injection in Patients With Advanced Cancers
Status:
Not yet recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
TQB2928 is a promising new molecular entity that mediates blockade of CD47 and SIRPĪ± and
enhances the phagocytosis of cancer cells by macrophages. In preclinical in vivo models,
TQB2928 was active against a wide range of solid tumors and hematologic malignancies. This is
the first-in-human phase 1 trial of TQB2928 in patients with advanced solid tumors and
hematological malignancies.